Oral Dextromethorphan for the Treatment of Diabetic Macular Edema: Results From a Phase I/II Clinical Study

David J Valent, Wai T Wong, Emily Y Chew, Catherine A Cukras, David J Valent, Wai T Wong, Emily Y Chew, Catherine A Cukras

Abstract

Purpose: The activation of microglia, the primary innate immune cell resident in the retina, produces inflammatory mediators, which underlie changes in diabetic retinopathy including increased vascular permeability. This study evaluates the safety and efficacy of dextromethorphan, a drug capable of inhibiting microglial activation, in the treatment of diabetic macular edema (DME).

Methods: A single-center, prospective, open-label phase I/II clinical trial enrolled five participants with macular involving DME who received oral dextromethorphan 60 mg twice daily for 6 months as monotherapy. Main outcome variables included central retinal subfield thickness (CST), best-corrected visual acuity (BCVA), macula sensitivity, and late leakage on fluorescein angiogram (FA).

Results: The study drug was well tolerated. At the primary end point of 6 months, mean CST decreased by -6.3% ± 6.8% and BCVA increased by +0.6 ± 5.11 (mean ± SEM) letters. Late leakage on FA was scored as improved in four of five study eyes. These findings were not correlated with changes in hemoglobin A1c (HbA1c), creatinine, or blood pressure.

Conclusions: In this proof-of-concept study, dextromethorphan administration as the primary treatment for DME was associated with decreased vascular leakage, suggesting possible therapeutic effects. Additional studies investigating the modulation of microglial activation is warranted.

Translational relevance: These findings highlight microglial modulation as a potentially useful therapeutic strategy in the treatment of diabetic macular edema.

Keywords: diabetes; diabetic retinopathy; microglia; retina.

Figures

Figure 1
Figure 1
Longitudinal record of central macular thickness in study eyes (n = 5) as evaluated by SD-OCT. (Upper panels) Horizontal B-scans traversing the center of the fovea are shown for all study visits from baseline to month 6. (Lower panels) Topographic maps of macular thickness at baseline and month 6 with a superimposed ETDRS grid centered on the fovea. The numbers in the grid depict mean retinal thickness in each subfield in micrometers. Study eyes in participants 1, 3, and 5 demonstrated a decrease in overall macular thickness at month 6 relative to baseline. The study eye in participant 2 showed in redistribution in the position of macular edema, while that in participant 4 showed an increase in central edema.
Figure 2
Figure 2
Longitudinal record of central macular thickness in fellow eyes (n = 3) as evaluated by SD-OCT. (Upper panels) Horizontal B-scans traversing the center of the fovea are shown for all study visits from baseline to month 6. (Lower panels) Topographic maps of macular thickness at baseline and month 6 with a superimposed ETDRS grid centered on the fovea. The numbers in the grid depict mean retinal thickness in each subfield in micrometers. Relative to baseline, the qualifying eyes changed at month 6 in the following ways: participant 3, a slight improvement in macular thickness; participant 4, slight worsening; participant 5, worsening macular edema.
Figure 3
Figure 3
Longitudinal record of noncentral temporal macular thickness in two study eyes as evaluated by SD-OCT. (Upper panels) Horizontal B-scans traversing the center of the area of temporal edema are shown for the study eyes of participants 2 and 4. The ETDRS circle was repositioned to center on the area of temporal edema. A scan in the temporal location was not obtained for participant 2 at the month 2 study visit. The numbers in the grid depict mean retinal thickness in each subfield in micrometers. (Lower panels) Topographic maps of the temporal macular thickness; the area of temporal macular edema in the study eye of participant 2 demonstrated clear improvement, while that in participant 4 showed mild reductions in thickness.
Figure 4
Figure 4
Changes in macular thickness measurements from baseline in study and qualifying fellow eyes. (A) Percentage changes in CST (measured in the 1-mm diameter central subfield) from baseline are shown for individual study eyes (left, n = 5) and qualifying fellow eyes (right, n = 3). Each histogram column shows the percentage change in CST at all study visits (months 1, 2, 4, and 6) arranged in consecutive order. (B) Mean percentage change in CST for all study eyes (left, n = 5) and all qualifying eyes (right, n = 8) at all study visits. (C) CST (measured in the 1-mm diameter central subfield) are shown for individual study eyes (left, n = 5) and qualifying fellow eyes (right, n = 3). Each histogram column shows the CST at all study visits (baseline, months 1, 2, 4, and 6) arranged in consecutive order. (D) Mean percentage change in CMV (measured in the 3-mm diameter central subfields) for all study eyes (left, n = 5) and all qualifying eyes (right, n = 8) at all study visits. Column heights indicate means and error bars indicate standard error.
Figure 5
Figure 5
Change in BCVA from baseline in study and qualifying fellow eyes. (A) Changes in BCVA (letters) from baseline are shown for individual study eyes (left, n = 5) and qualifying fellow eyes (right, n = 3). Each histogram column shows the percentage change in CST at all study visits (months 1, 2, 4, and 6) arranged in consecutive order. (B) Mean change in BCVA for all study eyes (left, n = 5) and all qualifying eyes (right, n = 8) at all study visits. Column heights indicate means and error bars indicate standard error.
Figure 6
Figure 6
Changes in macular sensitivity measured using MP-1 microperimetry. (A) Changes of mean sensitivity from baseline to month 6 for each study eye (central radius 10°, dark column; central 5°, white columns). (B) The average change in macular sensitivity from baseline to month 6 for all study eyes (central radius 10°, dark column; central 5°, white columns).
Figure 7
Figure 7
Changes in retinal vascular leakage in late phase fluorescein angiograms from baseline and month 6 in study and qualifying fellow eyes. Late phases fluorescein angiograms in (A) study eyes (n = 5) and (B) qualifying fellow eyes (n = 3) were obtained and compared at baseline and month 6.

References

    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services; 2014.
    1. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304:649–656.
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464–1474.
    1. Ferris FL, III, Patz A. Macular edema: a major complication of diabetic retinopathy. Trans New Orleans Acad Ophthalmol. 1983;31:307–316.
    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–1806.
    1. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–358.
    1. Yu Y, Chen H, Su SB. Neuroinflammatory responses in diabetic retinopathy. J Neuroinflammation. 2015;12:141.
    1. Xu H, Chen M. Diabetic retinopathy and dysregulated innate immunity. Vision Res. 2017;139:39–46.
    1. Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients. Acta Ophthalmol. 2016;94:56–64.
    1. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–77.
    1. Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32:2150–2157.
    1. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–79.
    1. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20:1366–1369.
    1. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719–722.
    1. Grigsby JG, Cardona SM, Pouw CE, et al. The role of microglia in diabetic retinopathy. J Ophthalmol. 2014;2014:705783.
    1. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227–232.
    1. Vujosevic S, Bini S, Midena G, Berton M, Pilotto E, Midena E. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res. 2013;2013:491835.
    1. Arroba AI, Alcalde-Estevez E, Garcia-Ramirez M, et al. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. Biochim Biophys Acta. 2016;1862:1663–1674.
    1. Barber AJ, Antonetti DA, Kern TS, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210–2218.
    1. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–1565.
    1. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17:463–471.
    1. Ibrahim AS, El-Remessy AB, Matragoon S, et al. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes. 2011;60:1122–1133.
    1. Baptista FI, Aveleria CA, Castilho AF, Ambrosio AF. Elevated glucose and interleukin-1beta differentially affect retinal microglial cell proliferation. Mediators Inflamm. 2017;2017:4316316.
    1. Kermorvant-Duchemin E, Pinel AC, Lavalette S, et al. Neonatal hyperglycemia inhibits angiogenesis and induces inflammation and neuronal degeneration in the retina. PLoS One. 2013;8:e79545.
    1. Wang AL, Yu AC, He QH, Zhu X, Tso MO. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp Eye Res. 2007;84:905–913.
    1. Dong N, Chang L, Wang B, Chu L. Retinal neuronal MCP-1 induced by AGEs stimulates TNF-alpha expression in rat microglia via p38, ERK, and NF-kappaB pathways. Mol Vis. 2014;20:616–628.
    1. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(suppl 2):S253–S262.
    1. Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res. 2015;45:30–57.
    1. Ahmad S, El-Sherbiny NM, Jamal MS, et al. Anti-inflammatory role of sesamin in STZ induced mice model of diabetic retinopathy. J Neuroimmunol. 2016;295-296:47–53.
    1. Ibrahim AS, El-Shishtawy MM, Pena A, Jr, Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis. 2011;16:2033–2042.
    1. Mendiola AS, Garza R, Cardona SM, et al. Fractalkine signaling attenuates perivascular clustering of microglia and fibrinogen leakage during systemic inflammation in mouse models of diabetic retinopathy. Front Cell Neurosci. 2016;10:303.
    1. Miloudi K, Binet F, Wilson A, et al. Truncated netrin-1 contributes to pathological vascular permeability in diabetic retinopathy. J Clin Invest. 2016;126:3006–3022.
    1. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53:3865–3874.
    1. Scott IU, Jackson GR, Quillen DA, Klein R, Liao J, Gardner TW. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy: a randomized proof-of-concept clinical trial. JAMA Ophthalmol. 2014;132:1137–1142.
    1. Scott IU, Jackson GR, Quillen DA, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2014;132:535–543.
    1. Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5:29–51.
    1. Amantea D, Bagetta G. Drug repurposing for immune modulation in acute ischemic stroke. Curr Opin Pharmacol. 2016;26:124–130.
    1. Li G, Cui G, Tzeng NS, et al. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. Faseb J. 2005;19:489–496.
    1. Liu Y, Qin L, Zhang W, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 2003;305:212–218.
    1. Keller M, Griesmaier E, Auer M, et al. Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur J Neurosci. 2008;27:874–883.
    1. Thomas DM, Kuhn DM. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 2005;1050:190–198.
    1. Liu PY, Lin CC, Tsai WC, et al. Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers. J Thromb Haemost. 2008;6:1685–1692.
    1. Zhang W, Shin EJ, Wang T, et al. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J. 2006;20:2496–2511.
    1. Yang PP, Yeh GC, Huang EY, Law PY, Loh HH, Tao PL. Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice. J Biomed Sci. 2015;22:81.
    1. Lu XC, Shear DA, Graham PB, et al. Dual therapeutic effects of C-10068, a dextromethorphan derivative, against post-traumatic nonconvulsive seizures and neuroinflammation in a rat model of penetrating ballistic-like brain injury. J Neurotrauma. 2015;32:1621–1632.
    1. Pu B, Xue Y, Wang Q, Hua C, Li X. Dextromethorphan provides neuroprotection via anti-inflammatory and anti-excitotoxicity effects in the cortex following traumatic brain injury. Mol Med Rep. 2015;12:3704–3710.
    1. Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis. 2011;44:63–72.
    1. Xu X, Zhang B, Lu K, et al. Prevention of hippocampal neuronal damage and cognitive function deficits in vascular dementia by dextromethorphan. Mol Neurobiol. 2016;53:3494–3502.
    1. Schafer DP, Heller CT, Gunner G, et al. Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression. Elife. 2016;5:e15224.
    1. Wong WT, Waynekid K, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010;51:6131–6139.
    1. Meleth AD, Wong WT, Chew EY. Treatment for atrophic macular degeneration. Curr Opin Ophthalmol. 2011;22:190–193.
    1. Colton CA, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987;223:284–288.
    1. Banati RB, Rothe G, Valet G, Kreutzberg GW. Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. Glia. 1993;7:183–191.
    1. Godbout JP, Berg BM, Kelley KW. Johnson RW. alpha-Tocopherol reduces lipopolysaccharide-induced peroxide radical formation and interleukin-6 secretion in primary murine microglia and in brain. J Neuroimmunol. 2004;149:101–109.
    1. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–2405.
    1. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
    1. Lattanzio R, Cicinelli MV, Bandello F. Intravitreal steroids in diabetic macular edema. Dev Ophthalmol. 2017;60:78–90.
    1. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625.
    1. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247–2254.
    1. Au A, Singh RP. A multimodal approach to diabetic macular edema. J Diabetes Complications. 2016;30:545–553.
    1. Trube G, Netzer R. Dextromethorphan: cellular effects reducing neuronal hyperactivity. Epilepsia. 1994;35(suppl 5):S62–S67.
    1. Carpenter CL, Marks SS, Watson DL, Greenberg DA. Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res. 1988;439:372–375.
    1. Chou YC, Liao JF, Chang WY, Lin MF, Chen CF. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999;821:516–519.
    1. Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007;13:272–293.
    1. Lisak RP, Nedelkoska L, Benjamins JA. Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules. Glia. 2014;62:751–762.
    1. Narita N, Hashimoto K, Iyo M, Minabe Y, Yamazaki K. Lack of neuroprotective effect of sigma receptor ligands in the neurotoxicity of p-chloroamphetamine in rat brain. Eur J Pharmacol. 1995;293:277–280.
    1. Cheng W, Li Y, Hou X, et al. Determining the neuroprotective effects of dextromethorphan in lipopolysaccharide-stimulated BV2 microglia. Mol Med Rep. 2015;11:1132–1138.
    1. Song JH, Yeh JZ. Dextromethorphan inhibition of voltage-gated proton currents in BV2 microglial cells. Neurosci Lett. 2012;516:94–98.
    1. Silverman SM, Wong WT. Microglia in the retina: roles in development, maturity, and disease. Annu Rev Vis Sci. 2018;4:45–77.
    1. Altmann C, Schmidt MHH. The role of microglia in diabetic retinopathy: inflammation, microvasculature defects and neurodegeneration. Int J Mol Sci. 2018;19:E110.
    1. Arroba AI, Valverde AM. Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol. 2017;54:527–533.
    1. Wang J, Chen S, Zhang X, Huang W, Jonas JB. Intravitreal triamcinolone acetonide, retinal microglia and retinal ganglion cell apoptosis in the optic nerve crush model. Acta Ophthalmol. 2016;94:e305–e311.
    1. Scholz R, Caramoy A, Bhuckory MB, et al. Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration. J Neuroinflammation. 2015;12:201.
    1. Brooks BR, Thisted RA, Appel SH, et al. AVP-923 ALS Study Group. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63:1364–1370.
    1. Panitch HS, Thisted RA, Smith RA, et al. Psuedobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59:780–787.
    1. Pioro EP, Brooks BR, Cummings J, et al. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693–702.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren